TF方案和FOLFOX6方案治疗晚期胃癌的临床观察
|
摘要
目的：比较TF方案和FOLFOX6方案治疗晚期胃癌的疗效及不良反应。方法：回顾性分析我院54例经病理确诊的晚期胃癌患者。A组28例,采用TF化疗方案：多西他赛50mg/m2,d1；CF400 mg/m2,d1；5-FU40 mg/m2,dl,5-FU2400～3000mg/m2,CⅣ(46小时),每14天为一周期,B组26例,采用FOLFOX6方案化疗：L-OHP100 mg/m2,d1；CF400 mg/m2,d1；5.FU400 mg/m2,d1,5-FU 2400-3000 mg/m2,CⅣ(46小时),每14天为一周期,对两组的近期疗效、生活质量改善情况、总生存期、无疾病进展时间、不良反应进行比较。结果：A组和B组的有效率分别为46.40%和46.20%,差异无统计学意义(P=0.99)。A组和B组的无疾病进展时间分别为5.5月,差异无统计学意义(P=0.54)。中位生存时间分别8.0月和8.5月,差异无统计学意义(P=0.71),A组和B组的生活质量改善为64.3%和30.80%差异有统计学意义(P=0.04)；两组主要不良反应白细胞减少、血红蛋白减少、恶心、呕吐、便秘等指标的差异具有显著性(P<0.05)。结论：TF方案和FOLFOX6方案在晚期胃癌的治疗方面近期疗效比较好,在不良反应以及生活质量改善情况等方面,TF方案优于FOLFOX6方案,具有更好的耐受性。
Objective:To compare the efficacy and toxicity of TF regimen and FOLFOX6 regimen on advanced gastric carcinoma (AGG) in gastric cancer. Methods:Retrospective analysis of 54 cases confirmed by pathology in patients with advanced gastric cancer,28 patients in group A treated with DF regimen:Docetaxel 50mg/m2,d1;CF400mg/m2,d1;5-FU400mg/ m2,d1;5-FU2400-3000mg/m2,CⅣV(46h), were given, repeated every 14 days; 26 patients in group B treated with FOLFOX6 regimen:L-OHP100 mg/m2,d1;CF400mg/m2,d1; 5-FU400mg/m2,d1;5-FU2400-3000mg/m2,CⅣ(46h), were given, repeated every 14 days.The efficacy,Progression Free Survival(PFS),overall survival (OS) improvement of QOL and toxicity of the two regimens were analyzed. Results:The response rate (RR) of group A and B were 46.40%and 46.20%,Difference was statistically significant(p=0.99). The median PFS was 5.50months in group A and5.50months in group B(P=0.54).The median survival time was 8.00 months in group A and 8.50 months in group B,Difference was statistically significant(p=0.71).The improvement rate of QOL of A and B were 64.30%and 30.80%,Difference was statistically significant(P= 0.04). Major side effect of the two groups had significant deference (P<0.05). Conclusion:Both TF and FOLFOX6 regimens were effective in treating advanced gastric cancer in patients. TF regimen is better than FOLFOX6 regimen on the improvement of QOL and toxicities survivability.
Objective:To compare the efficacy and toxicity of TF regimen and FOLFOX6 regimen on advanced gastric carcinoma (AGG) in gastric cancer. Methods:Retrospective analysis of 54 cases confirmed by pathology in patients with advanced gastric cancer,28 patients in group A treated with DF regimen:Docetaxel 50mg/m2,d1;CF400mg/m2,d1;5-FU400mg/ m2,d1;5-FU2400-3000mg/m2,CⅣV(46h), were given, repeated every 14 days; 26 patients in group B treated with FOLFOX6 regimen:L-OHP100 mg/m2,d1;CF400mg/m2,d1; 5-FU400mg/m2,d1;5-FU2400-3000mg/m2,CⅣ(46h), were given, repeated every 14 days.The efficacy,Progression Free Survival(PFS),overall survival (OS) improvement of QOL and toxicity of the two regimens were analyzed. Results:The response rate (RR) of group A and B were 46.40%and 46.20%,Difference was statistically significant(p=0.99). The median PFS was 5.50months in group A and5.50months in group B(P=0.54).The median survival time was 8.00 months in group A and 8.50 months in group B,Difference was statistically significant(p=0.71).The improvement rate of QOL of A and B were 64.30%and 30.80%,Difference was statistically significant(P= 0.04). Major side effect of the two groups had significant deference (P<0.05). Conclusion:Both TF and FOLFOX6 regimens were effective in treating advanced gastric cancer in patients. TF regimen is better than FOLFOX6 regimen on the improvement of QOL and toxicities survivability.
引文
[1]Rosati G,Ferrara D,Manzione L.New perspectives in the treatment of advanced or metastasis gastric cancer [J].World J Gastroenterol,2009,15(22):2689-2692.
[2]Fujitani K,Ajani JA,Crane CH,etal.Impact of induction chemothearpy and peropeartive chemoadrio thearpyon opeartive morbidity and moartlity in patients with locoergiona 1 adencoacrinma of the stomach or gastroesphagea 1 junction[J].Ann Surg Onco,1 2007,14(7):2010-2017.
[3]Greenlee RT,Murray T,Bolden S,etal.Cancer statistics,2000.CA Cancer J lin,2000, 50:7-332.
[4]Ajani J A.Chemotherapy for gastric carcinoma:new and old options.Oncology (Huntingt),1998,12(10 Suppl 7):44-47.
[5]Wagner AD,Grothe W,H aerting J,etal.Chemotherapy in advanced gastric cancer:a systematic review and m eta-ana lysisbased on aggregate data[J].JC 1 in Onco,l 2006,24(18):2903-2909.
[6]Burris HA 3rd,MooreMJ,Andersen J,etal.Imp rovements in survival and clinical benefitwith gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial [J].J Clin Oncol,1997,15(6):2403-2413.
[7]Murad AM,Santiago FF,Petroianu A,etal.Modified therapywith 5-fluorouracil, doxorubicin,and methotrexate in advanced gastric cancer[J].Cancer,1993,72:37-41.
[8]Pyrhonen S,Kuitunen T,Nyandoto P,etal.Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-respectable gastric cancer[J].Br J Cancer,1995,71:587-591.
[9]Wagner AD,Grothe W,Haerting J,etal.Chemotherapy in advancedgastric cancer:a systematic review and meta-analysis based on aggregate data[J].J Clin Oncol,2006, 24(18):2903-9.
[10]Ohtsu A,ShimadaY,Shirao K,etal.Randomized phase III trial of forouracil alone versus fluorouracil plus crisp Latin versus uracil and tegafurp lusmitomycin in patients with unresectable,advanced gastric cancer:The Japan Clinical Oncology Group Study (JCOG9205)[J].J Clin Oncol,2003,21:54-59.
[11]Scheithauer W,Konek G,Marczell A,etal.Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure 1-isomer of leucovrin for the treatment of advanced colorectal cancer:a random iced phase III study[J].J Clin Oncol,1997, 15:908.
[12]De Gramont A,Bosset JF,Milan C,etal:Randomized trial comp ring monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer:a French intergroup study[J] Clin,1997,15:808.
[13]储大同.当代肿瘤内科治疗方案评价[M].北京：北京大学医学出版社,2005：83-103.
[14]金懋林,陈强,程凤歧,等.奥沙利铂联合亚叶酸钙和5-氟尿嘧啶治疗晚期胃癌的研究[J].中华肿瘤杂志,2003,25(2)：172-4.
[15]江波,赵金奇,刘坤,等FOLFOX4方案和ECF方案治疗晚期胃癌的比较[J].临床肿瘤学杂志,2008,13(1)：43-45.
[16]Lim JY,Cho JY,Oh KJ,etal.Oxalip latin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with met static or recurrent gastric adenocarcinoma[J].Chemotherapy,2009,55(4):200-206.
[17]吴芳一,张弘纲,冉飞武,等FOLFOX6方案和DCF方案一线治疗晚期胃癌的疗效分析[J].癌症,2008,27(4)：413-417.
[18]肖卫FOLFOX4方案治疗晚期胃癌的疗效观察[J].现代肿瘤医学,2008,16(2)：241-243.
[19]Bang YJ,Kang WK,Kang YK,etal.Docetaxel 75 mg/m2 is active and well tolerated in patients with met static correcurent gastric cancer:A phase II trial [J].Jpn J Clin Oncol,2002,32:248.
[20]Graziano F,Catalano V,Baldelli AM,etal.A phase II study of weekly docetax elass alvage chemotherapy for advanced gastric cancer[J].Ann Onco 1,2000,11:1263.
[21]Ajani JA,Fodor MB,Tjulandin SA,etal.Phase II multiinstitutional randomized trial of docetaxelplus cisplatin with or without fluor ouracil in patient s with untreated,advanced gastric,orgast roesophageal adeno carcinoma[J].J Clin Onco 1,2005,23(24):5844.
[22]敖睿,刘浩,潘海霞FOLFOX4方案治疗晚期胃癌28例疗效观察[J].重庆医学,2009,38(6)：686.
[23]A1-Batran SE,Hartmann JT,Probst S,etal.Phase III trial inme2tastatic gastroesophageal adenocarcinoma with fluorouracil,leucovorin p lus either oxalip latin or cisp latin:a study of the Arbeitsgemeinschaft Internistische Onkologie [J]J Clin Oncol,2008,26.
[24]TrumperM,Ross PJ,Cunningham D,etal.Efficacy and tolerabili2ty of chemotherapy in elderly patientswith advanced oesophago-gastric cancer:A pooled analysis of three clinical trials[J].Eur JCancer,2006,42(7):827-834.(9):1435-1442.
[25]Takekida S,Fujiwara K,Nagao S,etal.Phase II study of combination chemotherapy with docetaxel and carboplatin for locally advanced or recurrent cervical cancer.Int J Gynecol Cancer.2010,20(9):1563-8.
[26]Wu H,Xin Y,Zhao J,etal.Metronomic docetaxel chemotherapy inhibits angiogenesis and tumor growth in a gastric cancer model.Cancer Chemother Pharmacol.2011,3. [Epub ahead of print]
[27]Egawa T,Kenmochi T,Ohashi M,etal.Highly advanced gastric cancer that responded to neoadjuvant combination chemotherapy with docetaxel/CDDP/S-1(DCS).Gan To Kagaku Ryoho.2010,37(12):2470-2.
[28]Shah MA,Jhawer M,Ilson DH,etal.Phase Ⅱ Study of Modified Docetaxel,Cisplatin, and Fluorouracil With Bevacizumab in Patients With Metastatic Gastroesophageal Adenocarcinoma.J Clin Oncol.2011,29(7):868-74.
[29]Jeung HC,Rha SY,Im CK,etal.A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.Cancer.2010,29.
[30]Yamamoto Y,Yoshida M,Sato M,etal.Feasibility of tailored,selective and effective anticancer chemotherapy by direct injection of docetaxel-loaded immunoliposomes into Her2/neu positive gastric tumor xenografts.Int J Oncol.2011,38(1):33-9.
[31]Nagase T,Kanai T,Nakagawa M,etal.Analysis of four patients with advanced gastric cancer undergoing gastrectomy after pre-operative combination chemotherapy using docetaxel,cisplatin and S-1.Gan To Kagaku Ryoho.2010,37(11):2177-9.
[32]Lim do H,Park SH,Park KW,etal.Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer.BMC Cancer.2010,10:583.
[33]Matsutani T,Uchida E,Maruyama H,etal.A successful resected case of far-advanced cancer at the esophagogastric junction by chemoradiotherapy with docetaxel, neda-platin and 5-fluorouracil.Gan To Kagaku Ryoho.2010,37(10):1949-52.
[34]Li CP,Chen JS,Chen LT,etal.A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer.Br J Cancer.2010,103(9):1343-8.
[35]Kim JA,Lee J,Han B,etal.Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.Cancer Chemother Pharmacol.2010,9.
[36]Breithaupt K,Thuss-Patience PC.Metastatic gastric cancer:does second-line chemo-therapy make sense Dtsch Med Wochenschr.2010,135(38):1872-6.
[37]Nukaya H,Kajino S,Tokuda H,etal.Bi-weekly docetaxel and doxifluridine combina-tion therapy in pretreated patients with unresectable and/or advanced gastric cancer.Gan To Kagaku Ryoho.2010 Sep;37(9):1713-7.
[38]Yu HB,Xian HB,Deng YM,Li LL.Therapeutic effects of FOLFOX6 versus TLF regimen as the first line chemotherapy for advanced gastric cancer.Nan Fang Yi Ke Da Xue Xue Bao.2010,30(10):2373-6.
[39]Han SW,Oh DY,Im SA,et al.Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6.Cancer Sci.2010 Mar;101(3):793-9.
[40]Ishii T,Kaneda I,Furuta A,etal.A case of advanced gastric and rectal cancer (double cancer) successfully treated with mFOLFOX6 therapy.Gan To Kagaku Ryoho.2009, 36(7):1171-4.
[41]Han SW,Oh DY,Im SA,etal.Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer.Br J Cancer.2009, 100(2):298-304.
[42]A1-Batran SE,Atmaca A,Hegewisch-Becker S,etal.Phase II trial of biweekly infusional fluorouracil,folinic acid,and oxaliplatin in patients with advanced gastric cancer.J Clin Oncol.2004,22(4):658-63.
[43]李晓琴,赵君慧,李积,FOLFOX6方案治疗进展期胃癌的临床观察[J],现代肿瘤学2006,14(1)：0062-0063
[44]邢晓静,张丽红,蔡玉文.多西他赛联合顺铂5-FU治疗进展期胃癌疗效分析[J].实用肿瘤学杂志,2006,20(6)：542-543.
[45]朱陵君,黄普文,卢凯华,等.多西他赛联合顺铂和氟尿嘧啶治疗进展期胃癌48例临床分析[J].肿瘤防治杂志,2005,12(23)：1804-1085.
[46]DeGramantA,LouvetC,AndreT, eta.l A review ofGERCO trials of bimonthly leucovorin plus 5-florouracil48 hour continous infusion in advanced colorectal cancer:evaluation of regimen[J].Eur J Cancer,1998,34(5):619-626.
[47]Webb A,Cunningham D,Scarffe JH,etal.Randomized tri-comparing epirubicin, cisplatin,and fluorom'acil versu fluorouracil doxorubicin,and methotrexate in advanced esophagogastric cancer [J] J Clin Oncol,1997,15(1):261-267.
[48]王彩莲,陈宝安.多西紫杉醇治疗晚期胃癌的进展[J].现代医学,2005,33(1)：53-55.
[49]Waters JS,Norman A,Cunningham D,etal.Long-term survival after epirubicin,cisplatin and fluorouracil for gastric cancer:results of a randomized trial [J].Br J Cancer,1999,80(1/2):269-272.
[50]Adjei AA,Argiris A,Murren JR.Docetaxel and irinotecan,alone and in combination,in the treatment of non—small cell lung cancer [J].Semin Oncol,1999,26(16):32-40.
[51]梁晓丽,夏路风,刘凤琴.多西紫杉醇的药理与临床应用[J]首都医学,1999,6(5)：28-29.
[52]Van Cutsam E,Moiseyenko VM,etal.PhaseIIIstudy of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group [J].Ann Oncol,2006, 24:4991-4997.
[53]Ajani JA,Moiseyenko VM,Tjulandin D,et al.Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase Ⅰ11 trial of advanced gastric or gastroesophageal cancer adenocarcinoma:the V325 Study Group[J].Ann Oncol,2007,25:3205-3209.
[54]Moiseyenko VM,Ajani JA,Tjulandin SA,etal.Final results of a randomized controlled phase III trial(TAX325) comparing docetaxel(T) combined with cisplatin(C) and 5-fluorouracil(F)(DCF) in patients(pts)with metastatic gastricadeno-carcinoma (MGC)[J].Proc Am Soc Clin Oncol,2005,23:Abstract 4002.
[55]Ajani J A,Moiseyenko V M,Tjulandin S,etal.Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phaseⅢtrial of advanced gastric orgastroesophageal cancer adenocarcinoma:the V-325 study group[J].J Clin Oncol,2007,25(22):3205-3209.
[56]Ajani J A,Moiseyenko V M,Tjulandin S,etal.Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phaseⅢtrial for advanced gastricor gastroesophageal adenocarcinoma:The V-325 Study Group[J].J Clin Oncol,2007,25(22):3210-3216.
[57]Louvet C,Andre T,Tigaud JM et al.Phase Ⅱ study of oxaliplatin,fluorouracil,and folinic acid in locally advanced or metastat ic gastric cancer patients[J].JCl in Oncol,2002,20:4543-8.
[58]D e Vita F,Orditura M,Matano E et al.Aphase Ⅱ study of biweekly oxaliplat in plus infusional 5-fluorouracil and folinic acid(FOLFOX-4)as first-line treatment of advanced gastric cancer patients[J].Br J Cancer,2005,92:1644-9.
[59][59] Lordick F,Lorenzen S,Stol lfuss J et al.Phase Ⅱ st udy of weekly oxaliplatin plus infusional f luorouracil and folinic acid(FUFOXregimen)as f irst-line t reatment inmetastatic gastric cancer[J].Br J Cancer,2005,93:190-4.
[60][60] A jani JA,Fodor MB,Tjulandin SA,etal.Phase Ⅱ multi-institutional randomized trial of docetaxel plus cisplat in with or without fluorouracil in patients with untreated,advanced gastric,or gastroesophageal adenocarcinoma[J].Journal of Clinical Oncology:official journal of the American Society of Clinical Oncology,2005,23(24): 5660-7.
[61]金懋林.最新胃癌化学治疗方案[M].北京：北京科学技术出社.
[62]肖卫FOLFOX4方案治疗晚期胃癌的疗效观察[J].现代肿瘤医学,2008,16(2)：241-243.
[63]Ajani JA,FodorMB,Tjulandin SA,etal.Phase Ⅱmulti-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patientswith untreated、 advanced gastric,or gastroe-sophageal adenocarcinoma[J].J Clin Onco,l 2005,23(24): 5660-5667.
[1]Rosati G,Ferrara D,Manzione L.New perspectives in the treatment of advanced or metastatic gastric cancer [J].World J Gastroenterol,2009,15(22):2689-2692.
[2]Hanazaki K,Sodeyama H,Yokoyama S,etal.Postoperat ive chemotherapy may improve prognosis in unresect able gastric cancer.J Clin Gastroenterol,1998,26 (4):269-73.
[3]Van Cutsen E,Moiseyenko V M,Tjulandin S,etal.PhaseIIIstudy of docetaxel and cisplatin plus fluorouracil compared withcisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 study group[J].J Clin Oncol,2006, 24(31):4991-4997.
[4]Ajani J A,Moiseyenko V M,Tjulandin S,etal.Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phaseⅢtrial of advanced gastric orgastroesophageal cancer adenocarcinoma:the V-325 study group[J] J Clin Oncol,2007,25(22):3205-3209.
[5]Ajani J A,Moiseyenko V M,Tjulandin S,etal.Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phaseⅢtrial for advanced gastricor gastroesophageal adenocarcinoma:The V-325 Study Group[J].J Clin Oncol,2007,25(22):3210-3216.
[6]AI-Batran S E,Hartmann J T,Probst S,etal.PhaseⅢtrial in metastatic gastroesophageal adenocarcinoma with fluorouracil,leucovorin plus either oxaliplatin or cisplatin:a study of the Ar-beitsgemeinschaft Intermistische Onkologie [J].J Clin Oncol,2008,26 (9):1435-1442.
[7]Ajani JA,Fodor MB,Tjulandin SA,etal.Phase Ⅱ multi-institutional randomized trial of docetaxel plus cisplat in with or without fluorouracil in patients with untreated,advanced gastric,or gastroesophageal adenocarcinoma[J].Journal of Clinical Oncology:official journal of the American Society of Clinical Oncology,2005, 23(24):5660-7.
[8]R oth AD,M aibach R,Falk S,etal.Docetaxel cisplat in 5 FU(TCF)versus docetaxel cisplatin(TC) versus epirubicin cisp lat in 5 FU(ECF)as system ic treatm en t for advanced gastric carcinoma(AGC):A random ized phase trial of th e Swiss Group for Clinical Cancer Research(SAKK)[J].Proc Am Soc Clin Oncol,2004,22:abstr 4020.
[9]M oiseyenk o VM,A jan i JA,T ju land in SA,etal.Final resu Its of arandom ized controlled phase trial(TA X 325) comparing docetaxel (T) combined with cisplat in(C) and 5-fluorouracil(F)to CF in patients(pts) with metastatic gastric adenocarcinom a(MGC)[J].Proc Am Soc Clin O nco,l 2005,23:abstr 4002.
[10]Louvet C,Andre T,Tigaud JM et al.Phase II study of oxaliplatin,fluorouracil,and folinic acid in locally advanced or metastat ic gastric cancer patients[J].JC1 in Oncol,2002,20:4543-8.
[11]D e Vita F,Orditura M,Matano E etal.Aphase II st udy of biweekly oxaliplat in plus infusional 5-fluorouracil and folinic acid(FOLFOX-4) as first-line treatment of advanced gastric cancer patient s[J].Br J Cancer,2005,92:1644-9.
[12]Lordick F,Lorenzen S,Stol lfuss J etal.Phase II st udy of weekly oxaliplatin plus infusional fluorouracil and folinic acid(FUFOXregimen)as first-line treatment inmetastatic gastric cancer[J].Br J Cancer,2005,93:190-4.
[13]A1-Batran S,Stohlmacher J,Probst S etal.Fluorouracil,leucovorin and oxaliplatin (FLO)versus fluorouracil,leucovorin andcisplat in(FLP)as a first-line therapy for patients with advanced gastric cancer;first interim analysis of a randomised multicenter phase II study[J].J Clin Oncol,2005,23:311s.
[14]O h SC,SurHY,Sung H J,etal.A phase II study of b wi eekly dosein tensif ied oral capecitab ine p lus irinotecan(bXELIRI)for patients with advanced or metastatic gastric cancer[J].Br J Cancer,2007,96(10):1514-9.
[15]Pozzo C,Barone C,Szanto J etal.Irinote can in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma:results of a randomized phase II study[J].Ann Oncol,2004,15:1773-81.
[16]Y ilmaz U,Oztop I,Alacacioglu A etal.Irinotecan combined with infusional 5-fluorouracil and high dose leucovorin(FOLFIRI) for the treatment of advanced gastric carcinoma as the first line chemotherapy[J] JC1 in Oncol,2005,23:348s.
[17]Boku N,Oht su A,Shimada Y et al.PhaseⅡ study of a combination of irinotecan and cisplat in against metastat ic gastric cancer[J].J Clin Oncol,1999,17:319-23.
[18]Pozzo C,Barone C,Szanto J etal.Irinote can in combinat ion with 5-fluoroura cil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma:results of a randomized phase Ⅱ study[J].Ann Oncol,2004, 15:1773-81.
[19]Koizumi W,Saigenji K,Ujiie S etal.A pilot phase Ⅱ study of capecitabine in advanced or recurrent gastric cancer[J].Oncology,2003;64:232-236.
[20]KangHJ,ChangHM,Kim TW,etal.A phase Ⅱ study ofpaclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer.Br JCancer,2008 98,(2):316-322.
[21]Koizumi W,Saigenji K,Ujiie S etal.A pilot phase Ⅱ study of capecitabine in advanced or recurrent gastric cancer[J].Oncology,2003;64:232-236.
[22]Park Y,Kim B,Ryoo B etal.Oxaliplatin and capecitabine combination chemot herapy for patients with advanced gastric carcinoma:a pilot study results[J]J Clin Oncol,2005,23:357s.
[23]Park Y,Kim B,Ryoo B etal.Oxaliplatin and capecitabine combination chemot herapy for patients w ith advanced gastric carcinoma:a pilot study results[J].J Clin Oncol,2005,23:357s.
[24][孙燕,石元凯.临床肿瘤内科手册[M].第5版.北京：人民卫生出版社,2007.846-847.
[25]Koizumi W,Akiya T,Sato A,etal.Phase Ⅱ study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer:the Tokyo Cooperative Oncology Group study[J].Cancer Chemother Pharmacol,2010,65(6): 1093-1099.
[2]Fujitani K,Ajani JA,Crane CH,etal.Impact of induction chemothearpy and peropeartive chemoadrio thearpyon opeartive morbidity and moartlity in patients with locoergiona 1 adencoacrinma of the stomach or gastroesphagea 1 junction[J].Ann Surg Onco,1 2007,14(7):2010-2017.
[3]Greenlee RT,Murray T,Bolden S,etal.Cancer statistics,2000.CA Cancer J lin,2000, 50:7-332.
[4]Ajani J A.Chemotherapy for gastric carcinoma:new and old options.Oncology (Huntingt),1998,12(10 Suppl 7):44-47.
[5]Wagner AD,Grothe W,H aerting J,etal.Chemotherapy in advanced gastric cancer:a systematic review and m eta-ana lysisbased on aggregate data[J].JC 1 in Onco,l 2006,24(18):2903-2909.
[6]Burris HA 3rd,MooreMJ,Andersen J,etal.Imp rovements in survival and clinical benefitwith gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial [J].J Clin Oncol,1997,15(6):2403-2413.
[7]Murad AM,Santiago FF,Petroianu A,etal.Modified therapywith 5-fluorouracil, doxorubicin,and methotrexate in advanced gastric cancer[J].Cancer,1993,72:37-41.
[8]Pyrhonen S,Kuitunen T,Nyandoto P,etal.Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-respectable gastric cancer[J].Br J Cancer,1995,71:587-591.
[9]Wagner AD,Grothe W,Haerting J,etal.Chemotherapy in advancedgastric cancer:a systematic review and meta-analysis based on aggregate data[J].J Clin Oncol,2006, 24(18):2903-9.
[10]Ohtsu A,ShimadaY,Shirao K,etal.Randomized phase III trial of forouracil alone versus fluorouracil plus crisp Latin versus uracil and tegafurp lusmitomycin in patients with unresectable,advanced gastric cancer:The Japan Clinical Oncology Group Study (JCOG9205)[J].J Clin Oncol,2003,21:54-59.
[11]Scheithauer W,Konek G,Marczell A,etal.Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure 1-isomer of leucovrin for the treatment of advanced colorectal cancer:a random iced phase III study[J].J Clin Oncol,1997, 15:908.
[12]De Gramont A,Bosset JF,Milan C,etal:Randomized trial comp ring monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer:a French intergroup study[J] Clin,1997,15:808.
[13]储大同.当代肿瘤内科治疗方案评价[M].北京：北京大学医学出版社,2005：83-103.
[14]金懋林,陈强,程凤歧,等.奥沙利铂联合亚叶酸钙和5-氟尿嘧啶治疗晚期胃癌的研究[J].中华肿瘤杂志,2003,25(2)：172-4.
[15]江波,赵金奇,刘坤,等FOLFOX4方案和ECF方案治疗晚期胃癌的比较[J].临床肿瘤学杂志,2008,13(1)：43-45.
[16]Lim JY,Cho JY,Oh KJ,etal.Oxalip latin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with met static or recurrent gastric adenocarcinoma[J].Chemotherapy,2009,55(4):200-206.
[17]吴芳一,张弘纲,冉飞武,等FOLFOX6方案和DCF方案一线治疗晚期胃癌的疗效分析[J].癌症,2008,27(4)：413-417.
[18]肖卫FOLFOX4方案治疗晚期胃癌的疗效观察[J].现代肿瘤医学,2008,16(2)：241-243.
[19]Bang YJ,Kang WK,Kang YK,etal.Docetaxel 75 mg/m2 is active and well tolerated in patients with met static correcurent gastric cancer:A phase II trial [J].Jpn J Clin Oncol,2002,32:248.
[20]Graziano F,Catalano V,Baldelli AM,etal.A phase II study of weekly docetax elass alvage chemotherapy for advanced gastric cancer[J].Ann Onco 1,2000,11:1263.
[21]Ajani JA,Fodor MB,Tjulandin SA,etal.Phase II multiinstitutional randomized trial of docetaxelplus cisplatin with or without fluor ouracil in patient s with untreated,advanced gastric,orgast roesophageal adeno carcinoma[J].J Clin Onco 1,2005,23(24):5844.
[22]敖睿,刘浩,潘海霞FOLFOX4方案治疗晚期胃癌28例疗效观察[J].重庆医学,2009,38(6)：686.
[23]A1-Batran SE,Hartmann JT,Probst S,etal.Phase III trial inme2tastatic gastroesophageal adenocarcinoma with fluorouracil,leucovorin p lus either oxalip latin or cisp latin:a study of the Arbeitsgemeinschaft Internistische Onkologie [J]J Clin Oncol,2008,26.
[24]TrumperM,Ross PJ,Cunningham D,etal.Efficacy and tolerabili2ty of chemotherapy in elderly patientswith advanced oesophago-gastric cancer:A pooled analysis of three clinical trials[J].Eur JCancer,2006,42(7):827-834.(9):1435-1442.
[25]Takekida S,Fujiwara K,Nagao S,etal.Phase II study of combination chemotherapy with docetaxel and carboplatin for locally advanced or recurrent cervical cancer.Int J Gynecol Cancer.2010,20(9):1563-8.
[26]Wu H,Xin Y,Zhao J,etal.Metronomic docetaxel chemotherapy inhibits angiogenesis and tumor growth in a gastric cancer model.Cancer Chemother Pharmacol.2011,3. [Epub ahead of print]
[27]Egawa T,Kenmochi T,Ohashi M,etal.Highly advanced gastric cancer that responded to neoadjuvant combination chemotherapy with docetaxel/CDDP/S-1(DCS).Gan To Kagaku Ryoho.2010,37(12):2470-2.
[28]Shah MA,Jhawer M,Ilson DH,etal.Phase Ⅱ Study of Modified Docetaxel,Cisplatin, and Fluorouracil With Bevacizumab in Patients With Metastatic Gastroesophageal Adenocarcinoma.J Clin Oncol.2011,29(7):868-74.
[29]Jeung HC,Rha SY,Im CK,etal.A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.Cancer.2010,29.
[30]Yamamoto Y,Yoshida M,Sato M,etal.Feasibility of tailored,selective and effective anticancer chemotherapy by direct injection of docetaxel-loaded immunoliposomes into Her2/neu positive gastric tumor xenografts.Int J Oncol.2011,38(1):33-9.
[31]Nagase T,Kanai T,Nakagawa M,etal.Analysis of four patients with advanced gastric cancer undergoing gastrectomy after pre-operative combination chemotherapy using docetaxel,cisplatin and S-1.Gan To Kagaku Ryoho.2010,37(11):2177-9.
[32]Lim do H,Park SH,Park KW,etal.Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer.BMC Cancer.2010,10:583.
[33]Matsutani T,Uchida E,Maruyama H,etal.A successful resected case of far-advanced cancer at the esophagogastric junction by chemoradiotherapy with docetaxel, neda-platin and 5-fluorouracil.Gan To Kagaku Ryoho.2010,37(10):1949-52.
[34]Li CP,Chen JS,Chen LT,etal.A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer.Br J Cancer.2010,103(9):1343-8.
[35]Kim JA,Lee J,Han B,etal.Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.Cancer Chemother Pharmacol.2010,9.
[36]Breithaupt K,Thuss-Patience PC.Metastatic gastric cancer:does second-line chemo-therapy make sense Dtsch Med Wochenschr.2010,135(38):1872-6.
[37]Nukaya H,Kajino S,Tokuda H,etal.Bi-weekly docetaxel and doxifluridine combina-tion therapy in pretreated patients with unresectable and/or advanced gastric cancer.Gan To Kagaku Ryoho.2010 Sep;37(9):1713-7.
[38]Yu HB,Xian HB,Deng YM,Li LL.Therapeutic effects of FOLFOX6 versus TLF regimen as the first line chemotherapy for advanced gastric cancer.Nan Fang Yi Ke Da Xue Xue Bao.2010,30(10):2373-6.
[39]Han SW,Oh DY,Im SA,et al.Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6.Cancer Sci.2010 Mar;101(3):793-9.
[40]Ishii T,Kaneda I,Furuta A,etal.A case of advanced gastric and rectal cancer (double cancer) successfully treated with mFOLFOX6 therapy.Gan To Kagaku Ryoho.2009, 36(7):1171-4.
[41]Han SW,Oh DY,Im SA,etal.Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer.Br J Cancer.2009, 100(2):298-304.
[42]A1-Batran SE,Atmaca A,Hegewisch-Becker S,etal.Phase II trial of biweekly infusional fluorouracil,folinic acid,and oxaliplatin in patients with advanced gastric cancer.J Clin Oncol.2004,22(4):658-63.
[43]李晓琴,赵君慧,李积,FOLFOX6方案治疗进展期胃癌的临床观察[J],现代肿瘤学2006,14(1)：0062-0063
[44]邢晓静,张丽红,蔡玉文.多西他赛联合顺铂5-FU治疗进展期胃癌疗效分析[J].实用肿瘤学杂志,2006,20(6)：542-543.
[45]朱陵君,黄普文,卢凯华,等.多西他赛联合顺铂和氟尿嘧啶治疗进展期胃癌48例临床分析[J].肿瘤防治杂志,2005,12(23)：1804-1085.
[46]DeGramantA,LouvetC,AndreT, eta.l A review ofGERCO trials of bimonthly leucovorin plus 5-florouracil48 hour continous infusion in advanced colorectal cancer:evaluation of regimen[J].Eur J Cancer,1998,34(5):619-626.
[47]Webb A,Cunningham D,Scarffe JH,etal.Randomized tri-comparing epirubicin, cisplatin,and fluorom'acil versu fluorouracil doxorubicin,and methotrexate in advanced esophagogastric cancer [J] J Clin Oncol,1997,15(1):261-267.
[48]王彩莲,陈宝安.多西紫杉醇治疗晚期胃癌的进展[J].现代医学,2005,33(1)：53-55.
[49]Waters JS,Norman A,Cunningham D,etal.Long-term survival after epirubicin,cisplatin and fluorouracil for gastric cancer:results of a randomized trial [J].Br J Cancer,1999,80(1/2):269-272.
[50]Adjei AA,Argiris A,Murren JR.Docetaxel and irinotecan,alone and in combination,in the treatment of non—small cell lung cancer [J].Semin Oncol,1999,26(16):32-40.
[51]梁晓丽,夏路风,刘凤琴.多西紫杉醇的药理与临床应用[J]首都医学,1999,6(5)：28-29.
[52]Van Cutsam E,Moiseyenko VM,etal.PhaseIIIstudy of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group [J].Ann Oncol,2006, 24:4991-4997.
[53]Ajani JA,Moiseyenko VM,Tjulandin D,et al.Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase Ⅰ11 trial of advanced gastric or gastroesophageal cancer adenocarcinoma:the V325 Study Group[J].Ann Oncol,2007,25:3205-3209.
[54]Moiseyenko VM,Ajani JA,Tjulandin SA,etal.Final results of a randomized controlled phase III trial(TAX325) comparing docetaxel(T) combined with cisplatin(C) and 5-fluorouracil(F)(DCF) in patients(pts)with metastatic gastricadeno-carcinoma (MGC)[J].Proc Am Soc Clin Oncol,2005,23:Abstract 4002.
[55]Ajani J A,Moiseyenko V M,Tjulandin S,etal.Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phaseⅢtrial of advanced gastric orgastroesophageal cancer adenocarcinoma:the V-325 study group[J].J Clin Oncol,2007,25(22):3205-3209.
[56]Ajani J A,Moiseyenko V M,Tjulandin S,etal.Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phaseⅢtrial for advanced gastricor gastroesophageal adenocarcinoma:The V-325 Study Group[J].J Clin Oncol,2007,25(22):3210-3216.
[57]Louvet C,Andre T,Tigaud JM et al.Phase Ⅱ study of oxaliplatin,fluorouracil,and folinic acid in locally advanced or metastat ic gastric cancer patients[J].JCl in Oncol,2002,20:4543-8.
[58]D e Vita F,Orditura M,Matano E et al.Aphase Ⅱ study of biweekly oxaliplat in plus infusional 5-fluorouracil and folinic acid(FOLFOX-4)as first-line treatment of advanced gastric cancer patients[J].Br J Cancer,2005,92:1644-9.
[59][59] Lordick F,Lorenzen S,Stol lfuss J et al.Phase Ⅱ st udy of weekly oxaliplatin plus infusional f luorouracil and folinic acid(FUFOXregimen)as f irst-line t reatment inmetastatic gastric cancer[J].Br J Cancer,2005,93:190-4.
[60][60] A jani JA,Fodor MB,Tjulandin SA,etal.Phase Ⅱ multi-institutional randomized trial of docetaxel plus cisplat in with or without fluorouracil in patients with untreated,advanced gastric,or gastroesophageal adenocarcinoma[J].Journal of Clinical Oncology:official journal of the American Society of Clinical Oncology,2005,23(24): 5660-7.
[61]金懋林.最新胃癌化学治疗方案[M].北京：北京科学技术出社.
[62]肖卫FOLFOX4方案治疗晚期胃癌的疗效观察[J].现代肿瘤医学,2008,16(2)：241-243.
[63]Ajani JA,FodorMB,Tjulandin SA,etal.Phase Ⅱmulti-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patientswith untreated、 advanced gastric,or gastroe-sophageal adenocarcinoma[J].J Clin Onco,l 2005,23(24): 5660-5667.
[1]Rosati G,Ferrara D,Manzione L.New perspectives in the treatment of advanced or metastatic gastric cancer [J].World J Gastroenterol,2009,15(22):2689-2692.
[2]Hanazaki K,Sodeyama H,Yokoyama S,etal.Postoperat ive chemotherapy may improve prognosis in unresect able gastric cancer.J Clin Gastroenterol,1998,26 (4):269-73.
[3]Van Cutsen E,Moiseyenko V M,Tjulandin S,etal.PhaseIIIstudy of docetaxel and cisplatin plus fluorouracil compared withcisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 study group[J].J Clin Oncol,2006, 24(31):4991-4997.
[4]Ajani J A,Moiseyenko V M,Tjulandin S,etal.Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phaseⅢtrial of advanced gastric orgastroesophageal cancer adenocarcinoma:the V-325 study group[J] J Clin Oncol,2007,25(22):3205-3209.
[5]Ajani J A,Moiseyenko V M,Tjulandin S,etal.Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phaseⅢtrial for advanced gastricor gastroesophageal adenocarcinoma:The V-325 Study Group[J].J Clin Oncol,2007,25(22):3210-3216.
[6]AI-Batran S E,Hartmann J T,Probst S,etal.PhaseⅢtrial in metastatic gastroesophageal adenocarcinoma with fluorouracil,leucovorin plus either oxaliplatin or cisplatin:a study of the Ar-beitsgemeinschaft Intermistische Onkologie [J].J Clin Oncol,2008,26 (9):1435-1442.
[7]Ajani JA,Fodor MB,Tjulandin SA,etal.Phase Ⅱ multi-institutional randomized trial of docetaxel plus cisplat in with or without fluorouracil in patients with untreated,advanced gastric,or gastroesophageal adenocarcinoma[J].Journal of Clinical Oncology:official journal of the American Society of Clinical Oncology,2005, 23(24):5660-7.
[8]R oth AD,M aibach R,Falk S,etal.Docetaxel cisplat in 5 FU(TCF)versus docetaxel cisplatin(TC) versus epirubicin cisp lat in 5 FU(ECF)as system ic treatm en t for advanced gastric carcinoma(AGC):A random ized phase trial of th e Swiss Group for Clinical Cancer Research(SAKK)[J].Proc Am Soc Clin Oncol,2004,22:abstr 4020.
[9]M oiseyenk o VM,A jan i JA,T ju land in SA,etal.Final resu Its of arandom ized controlled phase trial(TA X 325) comparing docetaxel (T) combined with cisplat in(C) and 5-fluorouracil(F)to CF in patients(pts) with metastatic gastric adenocarcinom a(MGC)[J].Proc Am Soc Clin O nco,l 2005,23:abstr 4002.
[10]Louvet C,Andre T,Tigaud JM et al.Phase II study of oxaliplatin,fluorouracil,and folinic acid in locally advanced or metastat ic gastric cancer patients[J].JC1 in Oncol,2002,20:4543-8.
[11]D e Vita F,Orditura M,Matano E etal.Aphase II st udy of biweekly oxaliplat in plus infusional 5-fluorouracil and folinic acid(FOLFOX-4) as first-line treatment of advanced gastric cancer patient s[J].Br J Cancer,2005,92:1644-9.
[12]Lordick F,Lorenzen S,Stol lfuss J etal.Phase II st udy of weekly oxaliplatin plus infusional fluorouracil and folinic acid(FUFOXregimen)as first-line treatment inmetastatic gastric cancer[J].Br J Cancer,2005,93:190-4.
[13]A1-Batran S,Stohlmacher J,Probst S etal.Fluorouracil,leucovorin and oxaliplatin (FLO)versus fluorouracil,leucovorin andcisplat in(FLP)as a first-line therapy for patients with advanced gastric cancer;first interim analysis of a randomised multicenter phase II study[J].J Clin Oncol,2005,23:311s.
[14]O h SC,SurHY,Sung H J,etal.A phase II study of b wi eekly dosein tensif ied oral capecitab ine p lus irinotecan(bXELIRI)for patients with advanced or metastatic gastric cancer[J].Br J Cancer,2007,96(10):1514-9.
[15]Pozzo C,Barone C,Szanto J etal.Irinote can in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma:results of a randomized phase II study[J].Ann Oncol,2004,15:1773-81.
[16]Y ilmaz U,Oztop I,Alacacioglu A etal.Irinotecan combined with infusional 5-fluorouracil and high dose leucovorin(FOLFIRI) for the treatment of advanced gastric carcinoma as the first line chemotherapy[J] JC1 in Oncol,2005,23:348s.
[17]Boku N,Oht su A,Shimada Y et al.PhaseⅡ study of a combination of irinotecan and cisplat in against metastat ic gastric cancer[J].J Clin Oncol,1999,17:319-23.
[18]Pozzo C,Barone C,Szanto J etal.Irinote can in combinat ion with 5-fluoroura cil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma:results of a randomized phase Ⅱ study[J].Ann Oncol,2004, 15:1773-81.
[19]Koizumi W,Saigenji K,Ujiie S etal.A pilot phase Ⅱ study of capecitabine in advanced or recurrent gastric cancer[J].Oncology,2003;64:232-236.
[20]KangHJ,ChangHM,Kim TW,etal.A phase Ⅱ study ofpaclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer.Br JCancer,2008 98,(2):316-322.
[21]Koizumi W,Saigenji K,Ujiie S etal.A pilot phase Ⅱ study of capecitabine in advanced or recurrent gastric cancer[J].Oncology,2003;64:232-236.
[22]Park Y,Kim B,Ryoo B etal.Oxaliplatin and capecitabine combination chemot herapy for patients with advanced gastric carcinoma:a pilot study results[J]J Clin Oncol,2005,23:357s.
[23]Park Y,Kim B,Ryoo B etal.Oxaliplatin and capecitabine combination chemot herapy for patients w ith advanced gastric carcinoma:a pilot study results[J].J Clin Oncol,2005,23:357s.
[24][孙燕,石元凯.临床肿瘤内科手册[M].第5版.北京：人民卫生出版社,2007.846-847.
[25]Koizumi W,Akiya T,Sato A,etal.Phase Ⅱ study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer:the Tokyo Cooperative Oncology Group study[J].Cancer Chemother Pharmacol,2010,65(6): 1093-1099.